Numerous minor histocompatibility antigens (MiHAs) show tissue-specific expression and can induce vigorous T cell responses. They therefore represent attractive targets for leukemia immunotherapy mediated by adoptive transfer of T cells. The main objective of this work was to determine whether MiHAs expressed by normal hematopoietic cells were present on leukemic cells and whether they could trigger lysis by cytotoxic T lymphocytes (CTLs). CTL assays showed that mouse leukemic cells of both lymphoid and myeloid lineages were sensitive to CTLs targeted toward some but not all MiHAs. In four out of four strain combinations in which we primed CTLs against immunodominant MiHAs, effectors killed leukemic blasts, whereas no cytotoxicity was observed when CTLs were targeted toward four immunorecessive MiHAs. Testing of HPLC fractions obtained from normal and leukemic cells provided molecular evidence that leukemic blasts expressed only some of the MiHAs found on normal mouse hematopoietic cells. Decreased density of H-2 class I molecules at the surface of leukemic cells suggests that down-regulation of genes encoding either class I molecules or proteins involved in antigen processing played a role in the aberrant expression of MiHAs. In vivo resistance to the leukemic cells by various strains of mice correlated with in vitro CTL activity. These results show that leukemic cells express only some (immunodominant) MiHAs and suggest that this subset of MiHAs represent prime targets for adoptive immunotherapy. (J. Clin. Invest. 1995. 95:1561-1568
Introduction
Both class I and class II MHC molecules bind and present self peptides that are derived from the proteolysis of endogenous 1 . Abbreviations used in this paper: CTL, cytotoxic T lymphocyte; GVHD, graft-versus-host disease; GVL, graft-versus-leukemia; MESF, molecules of equivalent soluble fluorochrome; MiHA, minor histocompatibility antigen; TFA, trifluoroacetic acid.
proteins (1, 2) . Some of these self peptides, known as minor histocompatibility antigens (MiHAs),' are polymorphic and can trigger T cell responses between MHC-identical individuals (3) (4) (5) . Expression of MiHAs as well as other nonpolymorphic MHC-associated self peptides contributes in shaping the T cell repertoire, since they influence both positive and negative selection (6) (7) (8) . Additionally, as T cells can detect a single amino acid substitution in MHC ligands, expression of self peptides allows T cells to check the integrity of the mammalian genome (gene -p endogenous protein -+ MHC-associated self peptide -+ target for immunosurveillance) (9, 10). Thus, T lymphocytes can reject cells that display abnormal self peptides after mutation, translocation, or viral infection (11, 12) .
MiHAs may represent ideal targets for cancer immunotherapy, since the expression of many of them is tissue specific and can trigger vigorous T cell responses (3, 13, 14) . This assertion is supported by the observation of the graft-versus-leukemia (GVL) effect after allogeneic bone marrow transplantation between MHC-identical/MiHA-different individuals (15, 16) . The remarkable strength of the anti-MiHA GVL effect provides the most convincing clinical evidence for the effectiveness of tumor immunity in man ( 17, 18) . The GVL reaction is initiated by donor T cells and can be triggered by as yet unidentified MiHAs that are expressed on normal hematopoietic cells (19) (20) (21) (22) . Unfortunately, the GVL effect is linked with graft-versushost disease (GVHD). However, since several MiHAs are tissue or cell lineage specific, it may be possible to dissociate GVHD and GVL effect at the clonal level (3, 1 1 ) . According to this hypothesis, the adoptive transfer of T cell clones that are directed against MiHAs expressed only by the host's hematopoietic cells, and absent on nonhematopoietic cells, could allow us to obtain a powerful GVL effect without GVHD. Such manipulation of T cell responses aimed at the eradication of leukemic cells requires fundamental knowledge regarding MiHA expression by these cells.
The goal of this work was to evaluate MiHA expression by lymphoid and myeloid leukemic cells. Specifically, we wanted to determine whether MiHAs expressed by normal hematopoietic cells were present on leukemic cells and whether they could trigger lysis by cytotoxic T lymphocytes (CTLs) . In addition, the relation between sensitivity to CTLs in vitro and in vivo resistance to leukemic cells was examined.
Methods
Mice. The following strains of mice were purchased from the Jackson Laboratory (Bar Harbor, ME): ABY/SnJ, C3H.SW/SnJ, C57BL/6J, B6.C-H-I b/By, B6.C-H-7b/By, B6.C-H-25c/By, B6.C-H-2d/aBy, C57BL/lOSnJ, BIO.LP-H-3b/Sn, BIO.129(21m)/SnH-4b, LP/J, and 129/J. All of these strains are H-2b except for B6.C-H-2d/aBy, which is H-2d. We used only male mice aged between 6 and 16 wk. All animals were maintained on acidified drinking water and under normal housing conditions according to the standards of the Canadian Committee for Animal Protection.
Tumor cells. The tumor cell lines used in this investigation were purchased from the American Type Culture Collection (Rockville, MD). EL-4 and C1498 are leukemic cell lines of C57BL/6J origin. EL-4 cells are T lymphoblasts, and C1498 are myeloblasts (23) . Both were maintained in DME supplemented with 100 U/ml penicillin G, 100 1g/ml streptomycin, 2 mM of L-glutamine, and either 10% horse serum (Hyclone, Logan, UT) for EL-4 or 10% FCS (Gibco Laboratories, Grand Island, NY) for C1498.
Generation of anti-MiHA CTLs. All mice except for BlO.LP-H-3b/ Sn and Bl0.129(21m)/SnH-4b were primed intraperitoneally with 2 x 107 cells of a 1:1 mixture of C57BL/6J spleen and bone marrow cells. BlO.LP-H-3b/Sn and B10.129(21m)/SnH-4b mice were immunized with C57BL/ 1OSnJ cells instead of C57BL/6J cells. Primed mice were killed 14 d after immunization, and their spleens were aseptically removed and crushed using a glass pylon to obtain a single-cell suspension. These CTL assay using peptidefractions. Lyophilized HPLC fractions were tested in a CTL assay using some modification to the CTL assay described earlier. Blast cells syngeneic to the effector cells were used as targets. These target cells were stimulated with 5 Ag/ml Con A for 48 h at 370C and then transferred to 260C for 18 h in order to increase the number of "empty" class I molecules (25) . Afterward, they were labeled at 370C with 100 qCi of Na25"Cr for 90 min and washed three times with RPMI + 5% FCS. Each HPLC fraction was resuspended in 200 jl of culture medium and sonicated for 15 min. 50 /d of each fraction was dispensed in triplicate into microtiter plates with U-shaped wells. In some experiments, dilutions were performed with the remaining 50 sl of each fraction (1:5, 1:10, 1:50). 5 X 1iO labeled target cells (50 sl) were then mixed with the peptide fractions and incubated for 90 min at 370C. Afterward To obtain the diameter of the different cells studied, we used the FACStarP"Us pulse-width processing. We calibrated the width scale with 6-mm singlet and doublet unlabeled beads. Using the forward scatter channel parameter, we could evaluate the diameter of the cell population. We then calculated the relative density of each class I molecule on the cell's surface using the following formula: class I density = total MESF value/4irr2 where r is the cell radius (MESF/ism2). (Fig. 1) . However, in three out of three experiments, lysis of leukemic cells tended to be slightly lower than that of Con A blasts at lower effector/target ratios, particularly for C1498 myeloblasts (Fig. 1) .
To get a more thorough evaluation of anti-MiHA CTL responses, we immunized effectors against the products of a single MiHA locus (H-1, H-7, H-9, H-25) or a single MiHA haplotype (H-3, H-4). Histocompatibility typing of mice used in these experiments is summarized in Table I . Lysis of EL-4 and C1498 by anti-H-3 and anti-H-4 CTLs was similar to that of Con A blasts (Fig. 2) . However, when CTLs were targeted to H-1, H-7, H-9, and H-25 MiHAs, we observed a clear dichotomy between Con A blasts and leukemic cells, as the latter were completely resistant to lysis. Collectively, these results show that susceptibility of leukemic cells to lysis depends on the specificity of CTL effectors. CTLs generated by immunization with cells differing at multiple MiHA loci (Fig. 1) or at a few MiHA loci that form a "complex" (H-3 and H-4) kill both normal and leukemic cells (29, 30) . However, the latter are resistant to CTLs directed against the product of a single MiHA locus.
In (Table II) . In naive recipients, LP/J and 129/J hosts showed a resistance to both C 1498 and EL-4 cells. Indeed, following challenge with C1498 cells, LP/J showed the same survival rate (80%) as B6.C-H-2d hosts, which are MHC-different from the leukemic cells. Other types of naive recipients showed a 100% mortality rate.
We also tested whether preimmunization of recipients with normal C57BL/6J cells could influence resistance to EL-4 cells. The six varieties of mice that generated CTLs able to kill leukemic cells (as depicted in Figs. 1 and 2 ) showed practically total resistance to EL-4 cells. In contrast, immunization did not protect the three types of recipients whose anti-C57BL/6J
MiHA CTLs were unable to lyse leukemic cells (B6.C-H-l b, B6.C-H-7b, and B6.C-H-25c).
Thus, there was a striking correlation between in vitro CTL- (37) .
Peptides from C57BL/6J blasts showed a complex HPLC elution profile (Fig. 3 a) . When individual fractions were tested for the presence of H-25b, fractions [22] [23] [24] were positive (Fig.  3 b) . These fractions were pooled and rechromatographed using a high resolution gradient (see Methods). After this second chromatography, positive fractions eluted with a single peak at 90-92 min (Fig. 4) . In contrast, no activity was found in any HPLC fractions eluted from the same number ( 109) of EL-4 or C1498 leukemic cells (data not shown). The absence of the target MiHA can explain why leukemic cells were resistant to anti-H-25b CTLs.
In the C3H.SW anti-C57BL/6J combination, MiHA activity was found in two HPLC fractions containing peptides eluted from Con A blasts (Fig. 5 a) . Similar results were previously observed with the BALB.B anti-C57BL/6J combination (28). Fraction 18 was active up to at least a 1:10 dilution, whereas activity of fraction 23 was lost after a dilution of 1:5. When leukemic cells were used as a source of peptides, fraction 18 had "normal" activity, but no other fraction sensitized targets to lysis (Fig. 5, b-c) (38, 39) . The fact that only mice producing antiMiHA CTLs able to kill leukemic cells in vitro could reject (or at least control) these leukemic cells in vivo suggests that antiMiHA CTL assays have biological relevance. Although we cannot prove that the CTLs detected in vitro are responsible for in vivo resistance, this is certainly a strong possibility. Indeed, it has been shown that class I-restricted CTLs can be directly cytopathic for their target cells in vivo (40) . A number of observations suggest that adoptive transfer of CTL clones targeted to hematopoietic MiHAs could generate a potent GVL ii_ g it H I It HI Figure 3 . Expression of H-25bMiHA.
(a) Standard (41) . To explain why leukemic cells were resistant to effectors immunized against a single MiHA (Fig. 2) , we assessed the expression of the two components of the specific ligand recognized by these CTLs: MHC class I molecules and MiHA peptides. We found a decreased cell surface density of some or all class I molecules on EL-4 and C1498 cells, respectively. This is consistent with studies on human leukemic cells in which a decreased expression of class I molecules was observed in cells of five out of six acute lymphoblastic leukemia patients by Van der Harst et al. (42) 32, 41, 47) . These were called immunodominant, whereas other MiHAs were said to be dominated or recessive. The molecular basis for this phenomenon remains unclear, although there is evidence that (i) it results from competition of MiHAs for processing or association with MHC molecules at the antigenpresenting cell level, and(ii) it may be influenced by the ability of some MiHAs to trigger both CD4 + and CD8 + T cell responses (28, 32,48). Accordingly, in the C3H.SW anti-C57BL/ 6J combination, we detected MiHAs in only two HPLC fractions, as did Yin et al. using BALB.B anti-C57BL/6J effectors (28). In four out of four strain combinations in which we primed CTLs against immunodominant MiHAs, effectors killed leukemic blasts (Fig. 1) . As a rule (one possible exception has been reported [28] ), CTLs generated in C57BL/6J congenic strains (differing from C57BL/6J by a single MiHA gene) recognize immunorecessive MiHAs (32, 47) . CTLs generated in four out of four strain combinations of this type killed normal but not leukemic blasts (Fig. 2) . These results provide strong evidence that only immunodominant MiHAs are well expressed at the surface of leukemic cells. H-3 and H-4 "haplotypes" probably represent an intermediate between these two extremes (first-order dominant MiHAs and totally recessive MiHAs), as there is a hierarchy in immunodominance (47) .
Additional studies will be required to understand the molecular bases for disturbed MiHA expression. Basal expression of MiHA peptides isgoverned mainly by three types of genes: genes encoding classic MHC molecules, those involved in anti-gen processing, and those encoding the MiHAs themselves. Down-regulated expression of the first two types of genes by neoplastic cells has been described and would be compatible with the low surface density of class I molecules we observed on EL-4 and C1498 leukemic blasts (34, 49 
